1. Updates and Insights on the Medical Science of Prostate Cancer

2. This program will include a discussion of off-label treatments and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Prostate Cancer Basic Facts

4. Biology of Bone Metastases in Prostate Cancer

5. Prostate Cancer Cells Induce Bone Remodeling

6. SREs in Prostate Cancer

7. Selected Bone-Targeted Therapies in mCRPC

8. Comparison of Antiresorptive Therapies for Bone Metastases

9. Denosumab vs Zoledronic Acid for Bone Metastases in CRPC

10. Antiresorptive Therapies Summary

11. Comparison of FDA-Approved AR Inhibitors

12. Selecting Abiraterone vs Enzalutamide

13. Phase 3 Trials of Abiraterone and Enzalutamide in Chemotherapy-Naive mCRPC

14. ODM-201 (Darolutamide) A Novel AR Inhibitor

15. ARADES Phase 1/2 Study of ODM-201 in Progressive mCRPC

16. ARADES Phase 1/2 Study of ODM-201 in Progressive mCRPC—Safety

17. ARASENS Randomized, Double-Blind, Phase 3 Trial of ODM-201 in Hormone-Sensitive mPC

18. Ongoing Issues Managing Nonmetastatic CRPC

19. Phase 3 Trial of Denosumab in Nonmetastatic CRPC

20. Phase 3 Trial of Denosumab in Nonmetastatic CRPC Results by PSADT

21. PROSPER Randomized, Double-Blind, Phase 3 Trial of Enzalutamide in Nonmetastatic CRPC

22. SPARTAN Randomized, Double-Blind, Phase 3 Trial of Apalutamide in Nonmetastatic CRPC

23. ARAMIS Randomized, Double-Blind, Phase 3 Trial of ODM-201 in High-Risk Nonmetastatic CRPC

24. Radium-223 A Novel Radioisotope

25. ALSYMPCA Randomized, Phase 3 Trial of Radium-223 in Symptomatic mCRPC

26. Phase 3b Expanded Access Trial of Radium-223

27. ALSYMPCA Subgroup Analysis According to Prior Docetaxel

28. CA184-043 Phase 3 Trial of Ipilimumab After Docetaxel in mCRPC

29. Phase 1 Trial of Tremelimumab + Short-Term ADT in PSA-Recurrent Prostate Cancer

30. Phase 2 Trial of Pembrolizumab in mCRPC Post-Enzalutamide

31. Phase 2 Study of Olaparib in mCRPC

32. Conclusions

33. Abbreviations

34. Abbreviations (cont)

35. Abbreviations (cont)